Valuation: argenx SE

Market Cap 56.88B 51.02B 46.63B 42.56B 80.19B 5,347B 82.72B 562B 224B 2,853B 214B 209B 9,007B P/E 2026 *
30.1x
P/E 2027 * 25.6x
Enterprise Value 53.06B 47.59B 43.49B 39.7B 74.8B 4,988B 77.16B 524B 209B 2,661B 199B 195B 8,401B EV / Sales 2026 *
8.27x
EV / Sales 2027 * 6.47x
Free-Float
99.99%
Yield 2026 *
0.07%
Yield 2027 * 0.11%
1 day+0.02%
1 week+1.07%
Current month+1.07%
1 month-2.72%
3 months+6.89%
6 months+21.54%
Current year+13.81%
1 week 776.6
Extreme 776.6
835.8
1 month 714.4
Extreme 714.4
835.8
Current year 568.4
Extreme 568.4
925
1 year 568.4
Extreme 568.4
925
3 years 271
Extreme 271
925
5 years 224.1
Extreme 224.1
925
10 years 12.5
Extreme 12.5
925
Manager TitleAgeSince
Chief Executive Officer 47 2026-05-05
Director of Finance/CFO 56 2021-05-31
Chief Tech/Sci/R&D Officer - 2014-12-31
Director TitleAgeSince
Chairman 54 2026-05-05
Director/Board Member 76 2015-05-12
Director/Board Member 65 2016-04-27
Date Insider Type Main position Quantity % Market Cap. Importance
11/23/25 Sell

Chief Executive Officer

2,000 0.0032%
11/23/25 Sell

Director

4,680 0.0076%
11/23/25 Exercice

Director

4,680 0.0076%
Change 5-day change 1-year change 3-year change Capi.($)
+0.02%+1.07%+11.72%+75.63% 56.88B
-4.83%+3.51%+55.00%+63.79% 66.7B
-1.34%+2.98%+25.08%+100.18% 56.53B
+5.09%+9.89%+27.19%+105.85% 46.49B
+2.62%+1.68%+29.16%+35.86% 44.8B
+8.24%+0.51%+215.16%+794.74% 41.59B
-1.86%+10.13%+28.14%+55.48% 35.35B
-2.97%-9.84%+90.91%+73.49% 33.29B
+5.19%+1.62%-39.69%+368.87% 25.1B
-2.18%+7.06%+40.97%-3.11% 24.92B
Average +0.80%+3.09%+48.36%+167.08% 43.16B
Weighted average by Cap. +0.49%+3.30%+49.39%+156.12%

Financials

2026 *2027 *
Net sales 6.42B 5.76B 5.26B 4.8B 9.05B 603B 9.33B 63.41B 25.29B 322B 24.09B 23.57B 1,016B 7.87B 7.06B 6.45B 5.89B 11.1B 740B 11.45B 77.76B 31.01B 395B 29.54B 28.91B 1,246B
Net income 1.83B 1.64B 1.5B 1.37B 2.58B 172B 2.66B 18.1B 7.22B 91.89B 6.88B 6.73B 290B 2.1B 1.88B 1.72B 1.57B 2.96B 197B 3.05B 20.73B 8.27B 105B 7.88B 7.71B 332B
Net Debt -3.83B -3.43B -3.14B -2.86B -5.39B -360B -5.56B -37.79B -15.07B -192B -14.36B -14.05B -606B -5.97B -5.35B -4.89B -4.46B -8.41B -561B -8.68B -58.95B -23.51B -299B -22.4B -21.92B -945B
Projected Income Statement - Annual - argenx SE
Logo argenx SE
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
Employees
1,863
Date Price Change Volume
26-11-06 €815.80 +0.02% 102,849
26-11-05 €815.60 +0.07% 109,168
26-11-04 €815.00 +3.32% 170,174
26-11-03 €788.80 +0.61% 92,256
26-11-02 €784.00 -2.87% 71,142
Trader
Investor
Global
Quality
ESG MSCI
A
MarketScreener Ratings - argenx SE
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
909.58USD
Average target price
1,120.50USD
Spread / Average Target
+23.19%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - argenx SE
  1. Stock Market
  2. Stocks
  3. ARGX Stock